0001392380-23-000050.txt : 20230801 0001392380-23-000050.hdr.sgml : 20230801 20230801175649 ACCESSION NUMBER: 0001392380-23-000050 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230728 FILED AS OF DATE: 20230801 DATE AS OF CHANGE: 20230801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cesarek Timothy J CENTRAL INDEX KEY: 0001774029 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35073 FILM NUMBER: 231133059 MAIL ADDRESS: STREET 1: 345 INVERNESS DRIVE SOUTH, BUILDING C STREET 2: SUITE 310 CITY: ENGLEWOOD STATE: CO ZIP: 80112 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gevo, Inc. CENTRAL INDEX KEY: 0001392380 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 870747704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 INVERNESS DRIVE SOUTH, BUILDING C STREET 2: Suite 310 CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: 303-858-8358 MAIL ADDRESS: STREET 1: 345 INVERNESS DRIVE SOUTH, BUILDING C STREET 2: Suite 310 CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: Gevo Inc DATE OF NAME CHANGE: 20070307 4 1 wk-form4_1690926998.xml FORM 4 X0508 4 2023-07-28 0 0001392380 Gevo, Inc. GEVO 0001774029 Cesarek Timothy J C/O GEVO, INC. 345 INVERNESS DRIVE SOUTH BUILDING C, SUITE 310 ENGLEWOOD CO 80112 0 1 0 0 Chief Commercial Officer 1 Common Stock 2023-07-28 4 S 0 37207 1.6434 D 831325 D The sales reported were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023. Represents shares sold by the Reporting Person to cover tax withholding obligations upon vesting of a restricted stock award. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.630 to $1.655 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Geoffrey T. Williams, Jr., Attorney-in-Fact 2023-08-01